The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis

Pedro N. Aguiar; Ilka Lopes Santoro; Hakaru Tadokoro; Gilberto De Lima Lopes; Bruno Andraus Filardi; Pedro Oliveira; Giannis Mountzios; Ramon Andrade De Mello

doi:10.2217/imt-2015-0002

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis

Pedro N. Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, Gilberto De Lima Lopes, Bruno Andraus Filardi, Pedro Oliveira, Giannis Mountzios, Ramon Andrade De Mello

School of Medicine

Research output: Contribution to journal › Review article › peer-review

90 Scopus citations

Abstract

Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

Original language	English (US)
Pages (from-to)	479-488
Number of pages	10
Journal	Immunotherapy
Volume	8
Issue number	4
DOIs	https://doi.org/10.2217/imt-2015-0002
State	Published - Apr 2016

Keywords

PD1
anti-PDL1
clinical trials
lung cancer
meta-analysis
nivolumab
non-small-lung cancer
pembrolizumab

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2015-0002

Cite this

@article{556b181fc34e49819aae03796cb43348,

title = "The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis",

abstract = "Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.",

keywords = "PD1, anti-PDL1, clinical trials, lung cancer, meta-analysis, nivolumab, non-small-lung cancer, pembrolizumab",

author = "Aguiar, {Pedro N.} and Santoro, {Ilka Lopes} and Hakaru Tadokoro and {De Lima Lopes}, Gilberto and Filardi, {Bruno Andraus} and Pedro Oliveira and Giannis Mountzios and {De Mello}, {Ramon Andrade}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = apr,

doi = "10.2217/imt-2015-0002",

language = "English (US)",

volume = "8",

pages = "479--488",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer

T2 - A network meta-analysis

AU - Aguiar, Pedro N.

AU - Santoro, Ilka Lopes

AU - Tadokoro, Hakaru

AU - De Lima Lopes, Gilberto

AU - Filardi, Bruno Andraus

AU - Oliveira, Pedro

AU - Mountzios, Giannis

AU - De Mello, Ramon Andrade

PY - 2016/4

Y1 - 2016/4

N2 - Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

AB - Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

KW - PD1

KW - anti-PDL1

KW - clinical trials

KW - lung cancer

KW - meta-analysis

KW - nivolumab

KW - non-small-lung cancer

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=84962597965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962597965&partnerID=8YFLogxK

U2 - 10.2217/imt-2015-0002

DO - 10.2217/imt-2015-0002

M3 - Review article

C2 - 26973128

AN - SCOPUS:84962597965

SN - 1750-743X

VL - 8

SP - 479

EP - 488

JO - Immunotherapy

JF - Immunotherapy

IS - 4

ER -

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this